Boston Scientific announces EU and US approval of new pacemakers
12 May 2008
Boston Scientific Corporation (NYSE:BSX) has announced US Food and
Drug Administration (FDA) and CE Mark approval of its Altrua family of
pacemakers. The products are
The Altrua is Boston Scientific's most advanced pacemaker and
delivers enhanced therapies while maintaining its small size and battery
longevity. It is the first Boston Scientific-branded pacemaker to treat
bradycardia, a condition in which the heart beats too slowly (usually
less than 60 beats per minute) depriving the body of sufficient oxygen.
"FDA approval of Boston Scientific's Altrua family of pacemakers —
especially following the European approval of Altrua — further
demonstrates the significant progress we have made rebuilding our CRM
organization and reinvigorating our product pipeline," said Fred Colen,
Executive Vice President, Operations and Technology, Cardiac Rhythm
Management. "Pacemakers are the most implanted device in the cardiac
rhythm management industry and we look forward to making the Altrua
family broadly available to physicians and their patients."